CX-6258 hydrochloride hydratePan-Pim kinases Inhibitor CAS# 1353858-99-7 |
- SGI-1776 free base
Catalog No.:BCC2232
CAS No.:1025065-69-3
- LKB1 (AAK1 dual inhibitor)
Catalog No.:BCC1705
CAS No.:1093222-27-5
- CX-6258
Catalog No.:BCC1504
CAS No.:1202916-90-2
- AZD1208
Catalog No.:BCC2079
CAS No.:1204144-28-4
- SMI-4a
Catalog No.:BCC2233
CAS No.:438190-29-5
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 1353858-99-7 | SDF | Download SDF |
| PubChem ID | 74892460 | Appearance | Powder |
| Formula | C26H27Cl2N3O4 | M.Wt | 516.42 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : 25 mg/mL (48.41 mM; Need ultrasonic) | ||
| Chemical Name | (3E)-5-chloro-3-[[5-[3-(4-methyl-1,4-diazepane-1-carbonyl)phenyl]furan-2-yl]methylidene]-1H-indol-2-one;hydrate;hydrochloride | ||
| SMILES | CN1CCCN(CC1)C(=O)C2=CC=CC(=C2)C3=CC=C(O3)C=C4C5=C(C=CC(=C5)Cl)NC4=O.O.Cl | ||
| Standard InChIKey | ZOZTWDKBSOVPDP-LLDDCTHSSA-N | ||
| Standard InChI | InChI=1S/C26H24ClN3O3.ClH.H2O/c1-29-10-3-11-30(13-12-29)26(32)18-5-2-4-17(14-18)24-9-7-20(33-24)16-22-21-15-19(27)6-8-23(21)28-25(22)31;;/h2,4-9,14-16H,3,10-13H2,1H3,(H,28,31);1H;1H2/b22-16+;; | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | CX-6258 hydrochloride hydrate is a potent, orally efficacious Pim 1/2/3 kinase(IC50=5 nM/25 nM/16 nM) inhibitor with excellent biochemical potency and kinase selectivity.
IC50 Value: 5 nM/25 nM/16 nM (Pim 1/2/3) [1]
Target: pan-Pim
in vitro: CX-6258 inhibited Flt-3 and Pim-3 (IC50=0.134 and 0.016 uM). At 0.5 uM of CX-6258, only Pim-1, Pim-2, Pim-3, and Flt-3 of the 107 kinases tested were inhibited by more than 80%, showing excellent selectivity. CX-6258 was also shown to be a reversible inhibitor of Pim-1 (Ki=0.005 uM). CX-6258 showed robust antiproliferative potencies against all cell lines tested derived from human solid tumors and hematological malignancies. In mechanistic cellular assays with MV-4-11 human AML cells, (13) caused dose-dependent inhibition of the phosphorylation of 2 pro-survival proteins, Bad and 4E-BP1, at the Pim kinase specific sites S112 and S65 and T37/46, respectively[1]. Pim-1 inhibition using the small molecule inhibitor CX-6258 (12 mM, 3 h) diminishes endogenous NKX3.1 steady state levels in 22RV1 and LNCaP cells. CX-6258 treatment (12 mM, 3 h) treatment diminished steady-state levels of ectopic NKX3.1 in PC3 cells. CX-6258 treatment resulted in a significant reduction in NKX3.1 half-life. While ectopically expressed NKX3.1 in control cells had a half-life of _90 min, Pim-1 inhibition reduced the half-life to _52 min [2].
in vivo: CX-6258 showed dose-dependent efficacy in mice bearing MV-4-11 xenografts, with 45% and 75% TGI at 50 and 100 mg/kg/day, respectively. Treatment of mice bearing PC3 xenografts with CX-6258 p.o. 50 mg/kg was also well tolerated and produced 51% TGI. References: | |||||
CX-6258 hydrochloride hydrate Dilution Calculator
CX-6258 hydrochloride hydrate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.9364 mL | 9.682 mL | 19.3641 mL | 38.7282 mL | 48.4102 mL |
| 5 mM | 0.3873 mL | 1.9364 mL | 3.8728 mL | 7.7456 mL | 9.682 mL |
| 10 mM | 0.1936 mL | 0.9682 mL | 1.9364 mL | 3.8728 mL | 4.841 mL |
| 50 mM | 0.0387 mL | 0.1936 mL | 0.3873 mL | 0.7746 mL | 0.9682 mL |
| 100 mM | 0.0194 mL | 0.0968 mL | 0.1936 mL | 0.3873 mL | 0.4841 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
IC50 Value: 5 nM (Pim 1); 25 nM (Pim 2); 16 nM (Pim 3) [1] CX-6258 is a potent, orally efficacious pan-Pim kinases Inhibitor with excellent biochemical potency and kinase selectivity. in vitro: CX-6258 inhibited Flt-3 and Pim-3 (IC50=0.134 and 0.016 uM). At 0.5 uM of CX-6258, only Pim-1, Pim-2, Pim-3, and Flt-3 of the 107 kinases tested were inhibited by more than 80%, showing excellent selectivity. CX-6258 was also shown to be a reversible inhibitor of Pim-1 (Ki=0.005 uM). CX-6258 showed robust antiproliferative potencies against all cell lines tested derived from human solid tumors and hematological malignancies. In mechanistic cellular assays with MV-4-11 human AML cells, (13) caused dose-dependent inhibition of the phosphorylation of 2 pro-survival proteins, Bad and 4E-BP1, at the Pim kinase specific sites S112 and S65 and T37/46, respectively[1]. Pim-1 inhibition using the small molecule inhibitor CX-6258 (12 mM, 3 h) diminishes endogenous NKX3.1 steady state levels in 22RV1 and LNCaP cells. CX-6258 treatment (12 mM, 3 h) treatment diminished steady-state levels of ectopic NKX3.1 in PC3 cells. CX-6258 treatment resulted in a significant reduction in NKX3.1 half-life. While ectopically expressed NKX3.1 in control cells had a half-life of _90 min, Pim-1 inhibition reduced the half-life to _52 min [2]. in vivo: CX-6258 showed dose-dependent efficacy in mice bearing MV-4-11 xenografts, with 45% and 75% TGI at 50 and 100 mg/kg/day, respectively. Treatment of mice bearing PC3 xenografts with CX-6258 p.o. 50 mg/kg was also well tolerated and produced 51% TGI. Clinical trial: N/A
- 8-Prenyldaidzein
Catalog No.:BCN4711
CAS No.:135384-00-8
- 12alpha-Methoxygrandiflorenic acid
Catalog No.:BCN7771
CAS No.:135383-94-7
- 4'-Hydroxyisojasminin
Catalog No.:BCN7383
CAS No.:135378-09-5
- Isojasminin
Catalog No.:BCN7492
CAS No.:135378-08-4
- 5,7,3',4'-Tetrahydroxy-3-methoxy-8,5'-diprenylflavone
Catalog No.:BCN6848
CAS No.:1353676-65-9
- 8,8'-Bibaicalein
Catalog No.:BCN6549
CAS No.:135309-02-3
- MEN 10376
Catalog No.:BCC7133
CAS No.:135306-85-3
- 2''-O-Rhamnosylicariside II
Catalog No.:BCN3464
CAS No.:135293-13-9
- EW-7197
Catalog No.:BCC6467
CAS No.:1352608-82-2
- Pulchinenoside B
Catalog No.:BCN6554
CAS No.:135247-95-9
- Trijuganone C
Catalog No.:BCN3685
CAS No.:135247-94-8
- Pindolol
Catalog No.:BCC6881
CAS No.:13523-86-9
- Bullatine A
Catalog No.:BCN2374
CAS No.:1354-84-3
- KH CB19
Catalog No.:BCC6135
CAS No.:1354037-26-5
- ACT 335827
Catalog No.:BCC6346
CAS No.:1354039-86-3
- trans-Ned 19
Catalog No.:BCC7825
CAS No.:1354235-96-3
- JW 480
Catalog No.:BCC6142
CAS No.:1354359-53-7
- 7-O-Prenylscopoletin
Catalog No.:BCN3547
CAS No.:13544-37-1
- Rehmapicrogenin
Catalog No.:BCN8507
CAS No.:135447-39-1
- Strontium Ranelate
Catalog No.:BCC3858
CAS No.:135459-87-9
- Araliadiol
Catalog No.:BCC8835
CAS No.:1354638-93-9
- Cabazitaxel intermediate
Catalog No.:BCN7432
CAS No.:1354900-65-4
- CYM 50260
Catalog No.:BCC6259
CAS No.:1355026-60-6
- ML 190
Catalog No.:BCC6308
CAS No.:1355244-02-8
